Skip to content

Study · Randomized controlled trial · n = 44 · 2016

8 results

Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy.

Dutour A, Abdesselam I, Ancel P, Kober F, Mrad G, Darmon P, Ronsin O, Pradel V, Lesavre N, Martin JC, Jacquier A, Lefur Y, Bernard M, Gaborit B

Diabetes, obesity & metabolism31 May 2016Cited by 213 (Europe PMC)

PMID27106272 (opens in a new tab)DOI10.1111/dom.12680 (opens in a new tab)PepBankPUB-27106272
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese patients with type 2 diabetes, exenatide and reference treatment produced similar HbA1c improvements.

    In plain wordsExenatide and reference treatment improved HbA1c similarly in obese patients with type 2 diabetes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeHbA1c change
    Study

    n = 44

    Comparator
    Reference treatment according to French guidelines
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.7%
    exenatide
    HbA1c change
    −0.7%
    reference treatment

    Source sentences

    Summary
    Exenatide and reference treatment led to a similar improvement in HbA1c (-0.7 ± 0.3% vs. -0.7 ± 0.4%; p = 0.29), whereas significant weight loss was observed only in the exenatide group (-5.5 ± 1.2 kg vs. -0.2 ± 0.8 kg; p = 0.001 for the difference between groups).
    2 context sentences
    Summary · context
    A total of 44 obese subjects with type 2 diabetes uncontrolled on oral antidiabetic drugs were randomly assigned to receive exenatide or reference treatment according to French guidelines.
    Summary · context
    Epicardial adipose tissue (EAT), myocardial triglyceride content (MTGC), hepatic triglyceride content (HTGC) and pancreatic triglyceride content (PTGC) were assessed 45 min after a standardized meal with 3T magnetic resonance imaging and proton magnetic resonance spectroscopy before and after 26 weeks of treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese patients with type 2 diabetes, exenatide reduced weight more than reference treatment.

    In plain wordsExenatide reduced weight more than reference treatment in obese patients with type 2 diabetes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight change
    Study

    n = 44

    Comparator
    Reference treatment according to French guidelines
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Weight change
    −5.5 kg
    exenatide
    Weight change
    −0.2 kg
    reference treatment

    Source sentences

    Summary
    Exenatide and reference treatment led to a similar improvement in HbA1c (-0.7 ± 0.3% vs. -0.7 ± 0.4%; p = 0.29), whereas significant weight loss was observed only in the exenatide group (-5.5 ± 1.2 kg vs. -0.2 ± 0.8 kg; p = 0.001 for the difference between groups).
    2 context sentences
    Summary · context
    A total of 44 obese subjects with type 2 diabetes uncontrolled on oral antidiabetic drugs were randomly assigned to receive exenatide or reference treatment according to French guidelines.
    Summary · context
    Epicardial adipose tissue (EAT), myocardial triglyceride content (MTGC), hepatic triglyceride content (HTGC) and pancreatic triglyceride content (PTGC) were assessed 45 min after a standardized meal with 3T magnetic resonance imaging and proton magnetic resonance spectroscopy before and after 26 weeks of treatment.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In obese patients with type 2 diabetes, exenatide reduced epicardial adipose tissue compared with reference treatment.

    In plain wordsExenatide reduced fat around the heart more than reference treatment in obese patients with type 2 diabetes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseEpicardial adipose tissue
    Study

    n = 44

    Comparator
    Reference treatment according to French guidelines
    Outcome group
    Body composition · Cardiovascular
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    EAT change
    −8.8%
    exenatide
    EAT change
    −1.2%
    reference treatment

    Source sentences

    Summary
    Exenatide induced a significant reduction in EAT (-8.8 ± 2.1%) and HTGC (-23.8 ± 9.5%), compared with the reference treatment (EAT: -1.2 ± 1.6%, p = 0.003; HTGC: +12.5 ± 9.6%, p = 0.007).
    2 context sentences
    Summary · context
    A total of 44 obese subjects with type 2 diabetes uncontrolled on oral antidiabetic drugs were randomly assigned to receive exenatide or reference treatment according to French guidelines.
    Summary · context
    Epicardial adipose tissue (EAT), myocardial triglyceride content (MTGC), hepatic triglyceride content (HTGC) and pancreatic triglyceride content (PTGC) were assessed 45 min after a standardized meal with 3T magnetic resonance imaging and proton magnetic resonance spectroscopy before and after 26 weeks of treatment.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In obese patients with type 2 diabetes, exenatide reduced hepatic triglyceride content compared with reference treatment.

    In plain wordsExenatide reduced liver fat more than reference treatment in obese patients with type 2 diabetes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHepatic triglyceride content
    Study

    n = 44

    Comparator
    Reference treatment according to French guidelines
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    HTGC change
    −23.8%
    exenatide
    HTGC change
    12.5%
    reference treatment

    Source sentences

    Summary
    Exenatide induced a significant reduction in EAT (-8.8 ± 2.1%) and HTGC (-23.8 ± 9.5%), compared with the reference treatment (EAT: -1.2 ± 1.6%, p = 0.003; HTGC: +12.5 ± 9.6%, p = 0.007).
    2 context sentences
    Summary · context
    A total of 44 obese subjects with type 2 diabetes uncontrolled on oral antidiabetic drugs were randomly assigned to receive exenatide or reference treatment according to French guidelines.
    Summary · context
    Epicardial adipose tissue (EAT), myocardial triglyceride content (MTGC), hepatic triglyceride content (HTGC) and pancreatic triglyceride content (PTGC) were assessed 45 min after a standardized meal with 3T magnetic resonance imaging and proton magnetic resonance spectroscopy before and after 26 weeks of treatment.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In obese patients with type 2 diabetes, pancreatic triglyceride content did not differ significantly between exenatide and reference treatment.

    In plain wordsPancreatic fat did not differ significantly between exenatide and reference treatment in obese patients with type 2 diabetes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changePancreatic triglyceride content
    Study

    n = 44

    Comparator
    Reference treatment according to French guidelines
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant difference was observed in other ectopic fat stores, PTGC or MTGC.
    2 context sentences
    Summary · context
    A total of 44 obese subjects with type 2 diabetes uncontrolled on oral antidiabetic drugs were randomly assigned to receive exenatide or reference treatment according to French guidelines.
    Summary · context
    Epicardial adipose tissue (EAT), myocardial triglyceride content (MTGC), hepatic triglyceride content (HTGC) and pancreatic triglyceride content (PTGC) were assessed 45 min after a standardized meal with 3T magnetic resonance imaging and proton magnetic resonance spectroscopy before and after 26 weeks of treatment.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In obese patients with type 2 diabetes, myocardial triglyceride content did not differ significantly between exenatide and reference treatment.

    In plain wordsHeart muscle fat did not differ significantly between exenatide and reference treatment in obese patients with type 2 diabetes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeMyocardial triglyceride content
    Study

    n = 44

    Comparator
    Reference treatment according to French guidelines
    Outcome group
    Body composition · Cardiovascular
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    No significant difference was observed in other ectopic fat stores, PTGC or MTGC.
    2 context sentences
    Summary · context
    A total of 44 obese subjects with type 2 diabetes uncontrolled on oral antidiabetic drugs were randomly assigned to receive exenatide or reference treatment according to French guidelines.
    Summary · context
    Epicardial adipose tissue (EAT), myocardial triglyceride content (MTGC), hepatic triglyceride content (HTGC) and pancreatic triglyceride content (PTGC) were assessed 45 min after a standardized meal with 3T magnetic resonance imaging and proton magnetic resonance spectroscopy before and after 26 weeks of treatment.

Studies that did not test the peptide alone2

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 07HumanNot a test of Exenatide (exendin-4) aloneObservational studyMechanism

    Among exenatide recipients, liver fat reduction correlated with weight loss but not insulin resistance, adiponectin, HbA1c or fructosamin changes.

    In plain wordsLiver fat reduction in exenatide recipients correlated with weight loss, but not the reported metabolic marker changes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableLiver fat reduction correlates
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver

    Measurements

    Correlation of liver fat reduction with weight loss (r)
    0.47 r
    exenatide group

    Source sentences

    Summary
    In the group treated with exenatide, reductions in liver fat and EAT were not associated with homeostatic model assessment of insulin resistance index, adiponectin, HbA1c or fructosamin change, but were significantly related to weight loss (r = 0.47, p = 0.03, and r = 0.50, p = 0.018, respectively).
    2 context sentences
    Summary · context
    A total of 44 obese subjects with type 2 diabetes uncontrolled on oral antidiabetic drugs were randomly assigned to receive exenatide or reference treatment according to French guidelines.
    Summary · context
    Epicardial adipose tissue (EAT), myocardial triglyceride content (MTGC), hepatic triglyceride content (HTGC) and pancreatic triglyceride content (PTGC) were assessed 45 min after a standardized meal with 3T magnetic resonance imaging and proton magnetic resonance spectroscopy before and after 26 weeks of treatment.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 08HumanNot a test of Exenatide (exendin-4) aloneObservational studyMechanism

    Among exenatide recipients, epicardial fat reduction correlated with weight loss but not insulin resistance, adiponectin, HbA1c or fructosamin changes.

    In plain wordsHeart fat reduction in exenatide recipients correlated with weight loss, but not the reported metabolic marker changes.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableEpicardial fat reduction correlates
    Study

    n: not reported in source

    Outcome group
    Body composition · Cardiovascular

    Measurements

    Correlation of epicardial fat reduction with weight loss (r)
    0.5 r
    exenatide group

    Source sentences

    Summary
    In the group treated with exenatide, reductions in liver fat and EAT were not associated with homeostatic model assessment of insulin resistance index, adiponectin, HbA1c or fructosamin change, but were significantly related to weight loss (r = 0.47, p = 0.03, and r = 0.50, p = 0.018, respectively).
    2 context sentences
    Summary · context
    A total of 44 obese subjects with type 2 diabetes uncontrolled on oral antidiabetic drugs were randomly assigned to receive exenatide or reference treatment according to French guidelines.
    Summary · context
    Epicardial adipose tissue (EAT), myocardial triglyceride content (MTGC), hepatic triglyceride content (HTGC) and pancreatic triglyceride content (PTGC) were assessed 45 min after a standardized meal with 3T magnetic resonance imaging and proton magnetic resonance spectroscopy before and after 26 weeks of treatment.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT02042664

Effect of GLP-1 Receptor (GLP-1R) Agonists on Cardiac Function and on Epicardial Adipose Tissue (EAT) Volume and on Myocardial TG Content in Obese Diabetics

Assistance Publique Hopitaux De Marseillen = 44Jan 2011 to Jun 2015

Obesity · Diabetes

Trial pageClinicalTrials.govUpdated 7 May 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.